HCV Treatment
AASLD 2017: Model Shows Hepatitis C Treatment is Cost-Effective in Japan
- Details
- Category: HCV Treatment
- Published on Tuesday, 28 November 2017 00:00
- Written by Liz Highleyman
Treatment of chronic hepatitis C with direct-acting antivirals can lead to substantial savings by preventing the development of liver failure and liver cancer, according to a mathematical modeling study presented at the AASLD Liver Meeting in October in Washington, DC.
AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life
- Details
- Category: HCV Treatment
- Published on Tuesday, 31 October 2017 00:00
- Written by Liz Highleyman
People who were cured of hepatitis C with direct-acting antivirals had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to study results presented at the AASLD Liver Meeting last week in Washington, DC.
Merck Discontinues Development of Experimental Hepatitis C Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 12 October 2017 00:00
- Written by HIVandHepatitis.com
Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor grazoprevir, the NS5A inhibitor ruzasvir, and the HCV polymerase inhibitor uprifosbuvir. The second is a 2-drug combo containing ruzasvir and uprifosbuvir.
AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis
- Details
- Category: HCV Treatment
- Published on Tuesday, 31 October 2017 00:00
- Written by Liz Highleyman
Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people with liver cirrhosis, according to a pair of reports presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
Janssen Discontinues Hepatitis C Drug Development Program
- Details
- Category: HCV Treatment
- Published on Thursday, 21 September 2017 00:00
- Written by Janssen
Janssen Sciences announced last week that it will stop further development of its experimental hepatitis regimen containing AL-335, odalasvir, and simeprevir, as the market is saturated with effective therapies. It will instead focus on hepatitis B, which is seldom cured with existing antiviral medications.
More Articles...
- IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Experts Question Cochrane Review of Hepatitis C DAA Treatment
- New Hepatitis C Drugs Reduce Mortality Risk in First 18 Months After Treatment
- IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection
Web Design and Development by